Table 2 Statistical analysis of endpoints
Time | Relative Effect, Fingolimod | N | Relative Effect, IFN-β 1b | N | P-value Treatment Arm | P-value Time | P-value Interaction | |
|---|---|---|---|---|---|---|---|---|
mfVEP Latency | Baseline | 0.6889 (0.4692; 0.8060) | 5 | 0.2917 (0.2029; 0.4268) | 4 | 0.630 | 0.905 | 0.001 |
6 months | 0.3778 (0.2134; 0.6298) | 5 | 0.6250 (0.3622; 0.8020) | 4 | ||||
T2 Lesion Count | Baseline | 0.4500 (0.2635; 0.6684) | 5 | 0.5139 (0.2871; 0.7316) | 4 | 0.935 | 0.239 | 0.164 |
6 months | 0.5333 (0.3257; 0.7209) | 5 | 0.5069 (0.2423; 0.7653) | 4 | ||||
T2 Lesion Volume | Baseline | 0.5056 (0.3180; 0.6902) | 5 | 0.4167 (0.2184; 0.6738) | 4 | 0.696 | < 0.001 | 0.876 |
6 months | 0.5722 (0.3642; 0.7400) | 5 | 0.4861 (0.2654; 0.7161) | 4 | ||||
mfVEP Latency | Baseline | 0.6736 (0.3338; 0.8699) | 3 | 0.2569 (0.1119; 0.5675) | 3 | 0.400 | 0.773 | 0.004 |
3 months | 0.2778 (0.1084; 0.6384) | 3 | 0.7292 (0.5522; 0.8409) | 3 | ||||
6 months | 0.4514 (0.1781; 0.7694) | 3 | 0.6528 (0.2843; 0.8734) | 3 | ||||
12 months | 0.3125 (0.1371; 0.6153) | 3 | 0.6458 (0.4587; 0.7875) | 3 |